Significant minder exacerbaties: Natalizumab (Tysabri)

Translated title of the contribution: Drug profile: Significantly fewer exacerbations with natalizumab (Tysabri)

^*Corresponding author for this work

Research output: Contribution to journal › Short survey › Academic

Translated title of the contribution	Drug profile: Significantly fewer exacerbations with natalizumab (Tysabri)
Original language	Dutch
Pages (from-to)	34-37
Number of pages	4
Journal	Pharmaceutisch Weekblad
Volume	142
Issue number	10
Publication status	Published - 9 Mar 2007
Externally published	Yes

Access to Document

@article{cbe44e2f62b343e9be23aa66bc7d2936,

title = "Significant minder exacerbaties: Natalizumab (Tysabri)",

author = "L. Kuiper and Ruijgrok, \{E. J.\}",

year = "2007",

month = mar,

day = "9",

language = "Dutch",

volume = "142",

pages = "34--37",

journal = "Pharmaceutisch Weekblad",

issn = "0031-6911",

publisher = "Kon. Ned. Mij. ter Bevordering der Pharmacie (KNMP)",

number = "10",

}

TY - JOUR

T1 - Significant minder exacerbaties

T2 - Natalizumab (Tysabri)

AU - Kuiper, L.

AU - Ruijgrok, E. J.

PY - 2007/3/9

Y1 - 2007/3/9

UR - https://www.scopus.com/pages/publications/34147194803

UR - https://www.pw.nl/

M3 - Short survey

AN - SCOPUS:34147194803

SN - 0031-6911

VL - 142

SP - 34

EP - 37

JO - Pharmaceutisch Weekblad

JF - Pharmaceutisch Weekblad

IS - 10

ER -